Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

23.550
+0.2000.86%
Volume:5.50K
Turnover:129.53K
Market Cap:20.54B
PE:68.83
High:23.550
Open:23.550
Low:23.550
Close:23.350
Loading ...

BRIEF-HUTCHMED (China) Says NMPA Granted Full Approval For Orpathys (Savolitinib) In China

Reuters
·
14 Jan

- HUTCHMED China Ltd - Full Approval for Orpathys in China

THOMSON REUTERS
·
14 Jan

HUTCHMED (China) Ltd - Nmpa Full Approval for Orpathys (Savolitinib) in China

THOMSON REUTERS
·
14 Jan

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

GlobeNewswire
·
14 Jan

BofA Securities Cuts Price Target on HUTCHMED to $26 From $30, Maintains Buy Rating

MT Newswires Live
·
07 Jan

HUTCHMED (China) Ltd : Bofa Global Research Cuts Price Objective to $26 From $30

THOMSON REUTERS
·
07 Jan

Hutchmed Says China's Medicines Regulator Accepts NDA With Priority Review for Orpathys, Tagrisso Combination

MT Newswires Live
·
02 Jan

Deals of the day-Mergers and acquisitions

Reuters
·
02 Jan

HUTCHMED to Divest 45% Equity Stake in Shanghai Hutchison Pharmaceuticals for $608 Million

MT Newswires Live
·
02 Jan

HUTCHMED (China) Combination Cancer Treatment Gets NDA; Share Prices Up 5%

MT Newswires Live
·
02 Jan

HUTCHMED China Ltd - US$608M Divestment of Non-Core Joint Venture

THOMSON REUTERS
·
02 Jan

HUTCHMED (China) Ltd - Expects to Record Gain on Disposal of About $477 Mln Before Taxation

THOMSON REUTERS
·
02 Jan

HUTCHMED (China) Ltd - to Invest Proceeds in Developing Internal Pipeline

THOMSON REUTERS
·
02 Jan

BUZZ-HK-listed Hutchmed jumps on health unit stake sales

Reuters
·
02 Jan

Hutchmed Projects Gain of $477 Million From Hutchison Pharmaceutical Stake Disposal

MT Newswires Live
·
02 Jan

Stock Track | HUTCHMED Soars 5.99% on Positive Regulatory News for Lung Cancer Drug Combo

Stock Track
·
02 Jan

BRIEF-Hutchmed Says NDA Acceptance In China With Priority Review Status For Orpathys And Tagrisso Combination

Reuters
·
02 Jan

HUTCHMED Announces Nda Acceptance in China With Priority Review Status for Orpathys® and Tagrisso® Combination in Lung Cancer Patients With Met Amplification After Progression on First-Line Egfr Inhibitor Therapy

THOMSON REUTERS
·
02 Jan

HUTCHMED (China) Ltd - This Acceptance Also Triggers a Milestone Payment From AstraZeneca

THOMSON REUTERS
·
02 Jan

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

GlobeNewswire
·
02 Jan